Tag Archives: M&A

Therapeutic Licensing and M&A Deals

lab_tech

Licensing deals for therapeutic candidates in 2013 dropped to the lowest volume in at least eight years for deals with disclosed values totaling over $10M. Total upfront payments to biotechs were also at an eight year low, with only $1.9B paid to biotechs in 2013. This is a 50 percent drop from peak levels. However, there is a silver lining in the data: Preclinical deal volume saw a slight increase in 2013, and has not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO-Europe Spring Opening Remarks

Chart

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring conference in Barcelona yesterday. His slides provide a snapshot of the biotech industry’s performance and highlight emerging trends in venture exits: IPOs and M&A. Takeaways from his talk include breakouts on multiple fronts for the industry: FDA approvals at highs not seen since the 1990s Orphan designation approvals at all-time highs IPOs starting to show signs of life in 2012 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Putting a Ring on It: Advice on Successful Drug Development Collaborations

Ring

Drug development partnerships can look lucrative to small biotechs eager to monetize their discoveries, but, like any relationship, these tie-ups take work and both parties run the risk of ending up in tears. At BIO’s recent CEO & Investor Conference, a panel of industry veterans gathered to discuss best practices in drug development partnering. Moderated by Jeff Stewart, Senior Engagement Manager with Campbell Alliance, the panel “Putting a Ring on it: When Drug Development Partnerships Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Biobuck M&A in Full Gear

Graph

The 2012 M&A results are in and trends are mixed. Last year was a down year in terms of total acquisitions and total dollar value amounts vs 2011.  What was not down however was the earnout structures embedded in these deals. More and more M&A transactions are looking like partnering deals structured with CVRs accounting for the bolus of the reported purchase price. Here is a look at therapeutic-focused acquisitions (valued at >$10M) over the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,